Document:

EX-10.29

 Exhibit 10.29 

CONSULTING AGREEMENT 

This Consulting Agreement (the “Agreement”) is entered into on February 1, 2017, by and between Pieris Pharmaceuticals, Inc., a
Nevada corporation, with its principal place of business being Lise-Meitner-Strasse 30, 85354 Freising-Weihenstephan, Germany (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal
place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” 

WHEREAS, the Company is a U.S. publicly traded company that possesses know-how and proprietary technology related to the field of Anticalin® brand proteins; and 
 WHEREAS, Danforth has expertise in financial and corporate
operations and strategy, including financial reporting requirements for U.S. publicly traded companies; and 
 WHEREAS, Danforth desires to
serve as an independent consultant for the purpose of providing the Company with certain strategic and financial advice and support services, as more fully described in Exhibit A attached hereto, (the “Services”); and 

WHEREAS, the Company wishes to engage Danforth on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which are hereby acknowledged,
the Parties agree and covenant as follows. 
 1. Services of Consultant. Danforth will assist the Company with matters relating to
the Services commencing on the date that Lance Thibault is appointed as the Acting Chief Financial Officer of the Company (the “Effective Date”). The Services are more fully described in Exhibit A attached hereto. Danforth and the
Company will review the Services on a monthly basis to prioritize and implement the tasks listed on Exhibit A. 
 2. Compensation
for Services. In full consideration of Danforth’s full, prompt and faithful performance of the Services, the Company shall compensate Danforth a consulting fee more fully described in Exhibit A (the “Consulting Fee”).
Danforth shall, from time to time, but not more frequently than twice per calendar month, invoice the Company for Services rendered, and such invoice will be paid upon fifteen (15) days of receipt. Each month the Parties shall evaluate jointly
the current fee structure and scope of Services. Danforth reserves the right to an annual increase in consultant rates of up to 4%, effective January 1 of each year. Upon termination of this Agreement pursuant to Section 3, no compensation
or benefits of any kind as described in this Section 2 shall be payable or issuable to Danforth after the effective date of such termination. In addition, the Company will reimburse Danforth for reasonable out-of-pocket business expenses,
including but not limited to travel and parking, incurred by Danforth in performing the Services hereunder, upon submission by Danforth of supporting documentation reasonably acceptable to the Company. Any such accrued expenses in any given three
(3) month period that exceed one thousand dollars ($1,000) shall be submitted to the Company for its prior written approval. 

 All Danforth invoices and billing matters should be addressed to: 

 

			
	Company Accounts Payable Contact:	  	[NAME]
		  	[EMAIL ADDRESS]
		  	[PHONE NUMBER]
		  	[ADDRESS]

 All Company payments and billing inquiries should be addressed to: 

 

					
	Danforth Accounting:	  	Danforth Advisors	  	
		  	PO Box 335	  	
		  	Southborough, MA 01772	  	

 3. Term and Termination. The term of this Agreement will commence on the Effective Date and will
continue through the anniversary of such date in the next calendar year (the “Term”). This Agreement may be extended for an additional period by mutual written agreement. This Agreement may be terminated by either Party hereto:
(a) with Cause (as defined below), upon thirty (30) days prior written notice to the other Party; or (b) without cause upon sixty (60) days prior written notice to the other Party. For purposes of this Section 3,
“Cause” shall include: (i) a breach of the terms of this Agreement which is not cured within thirty (30) days of written notice of such default or (ii) the commission of any act of fraud, embezzlement or deliberate disregard
of a rule or policy of the Company. 
 4. Time Commitment. Danforth will devote such time to perform the Services under this
Agreement as may reasonably be required. 
 5. Place of Performance. Danforth will perform the Services at such locations upon which
the Company and Danforth may mutually agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any facility or in any manner that might give anyone other than the Company any rights to or allow for
disclosure of any Confidential Information (as defined below). 
 6. Compliance with Policies and Guidelines. Danforth will perform
the Services in accordance with all rules or policies adopted by the Company that the Company discloses in writing to Danforth. 
 7.
Confidential Information. Danforth acknowledges and agrees that during the course of performing the Services, the Company may furnish, disclose or make available to Danforth information, including, but not limited to, material, compilations,
data, formulae, models, patent disclosures, procedures, processes, business plans, projections, protocols, results of experimentation and testing, specifications, strategies and techniques, and all tangible and intangible embodiments thereof of any
kind whatsoever (including, but not limited to, any apparatus, biological or chemical materials, animals, cells, compositions, documents, drawings, machinery, patent applications, records and reports), which is owned or controlled by the Company and
is marked or designated as confidential at the time of disclosure or is of a type that is customarily considered to be confidential information (collectively the “Confidential Information”). Danforth acknowledges that the Confidential
Information or any part thereof is the exclusive property of the Company and shall not be disclosed to any third party without first 

  
 2 

 
obtaining the written consent of the Company. Danforth further agrees to take all practical steps to ensure that the Confidential Information, and any part thereof, shall not be disclosed or
issued to its affiliates, agents or employees, except on like terms of confidentiality. The above provisions of confidentiality shall apply for a period of five (5) years. 

8. Intellectual Property. Danforth agrees that all ideas, inventions, discoveries, creations, manuscripts, properties, innovations,
improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, and formulae that Danforth conceives, makes, develops or improves as a result of performing the Services, whether or not reduced to practice and whether or
not patentable, alone or in conjunction with any other party and whether or not at the request or upon the suggestion of the Company (all of the foregoing being hereinafter collectively referred to as the “Inventions”), shall be the sole
and exclusive property of the Company. Danforth hereby agrees in consideration of the Company’s agreement to engage Danforth and pay compensation for the Services rendered to the Company and for other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged that Danforth shall not, without the prior written consent of the Company, directly or indirectly, consult for, or become an employee of, any company which conducts business in the Field of
Interest anywhere in the world. As used herein, the term “Field of Interest” shall mean the research, development, manufacture and/or sale of the products resulting from the Company’s technology. The limitations on competition
contained in this Section 8 shall continue during the time that Danforth performs any Services for the Company, and for a period of three (3) months following the termination of any such Services that Danforth performs for the Company. If
any part of this section should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or scope, then this Section 8 is intended to and shall extend only for such period of time, in such area and
with respect to such activity as is determined to be reasonable. Except as expressly provided herein, nothing in this Agreement shall preclude Danforth from consulting for or being employed by any other person or entity. 

9. Non Solicitation. All personnel representing Danforth are employees or contracted agents of Danforth. As such, they are obligated to
provide the Services to the Company and are obligated to Danforth under confidentiality, non-compete, and non-solicitation agreements. Accordingly, they are not retainable as employees or contractors by the Company and the Company hereby agrees not
to solicit, hire or retain their services for so long as they are employees or contracted agents of Danforth and for two (2) years thereafter. Should the Company violate this restriction, it agrees to pay Danforth liquidated damages equal to
equal to thirty percent (30%) of the employee’s starting annual base salary and target annual bonus for each Danforth contracted agent hired by the Company in violation of this Agreement, plus Danforth’s reasonable attorneys’
fees and costs incurred in enforcing this agreement should the Company fail or refuse to pay the liquidated damages amount in full within thirty (30) days following its violation. 

10. Placement Services. In the event that Danforth refers a potential employee to the Company and that individual is hired, Danforth
shall receive a fee equal to ten percent (10%) of the employee’s starting annual base salary. This fee is due and owing whether an individual is hired, directly or indirectly on a permanent basis or on a contract or consulting basis by the
Company, as a result of Danforth’s efforts within one (1) year of the date applicant(s) are submitted to the Company. Such payment is due within thirty (30) days of the employee’s start date. 

  
 3 

 11. No Implied Warranty. Except for any express warranties stated herein, the Services are
provided on an “as is” basis, and the Company disclaims any and all other warranties, conditions, or representations (express, implied, oral or written), relating to the Services or any part thereof. Further, in performing the Services
Danforth is not engaged to disclose illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding, Danforth will promptly notify the Company if Danforth becomes aware of any such illegal acts during the
performance of the Services. Because the Services do not constitute an examination in accordance with standards established by the American Institute of Certified Public Accountants (the “AICPA”), Danforth is precluded from expressing an
opinion as to whether financial statements provided by the Company are in conformity with generally accepted accounting principles or any other standards or guidelines promulgated by the AICPA, or whether the underlying financial and other data
provide a reasonable basis for the statements. 
 12. Indemnification. Each Party hereto agrees to indemnify and hold the other Party
hereto, its directors, officers, agents and employees harmless against any claim based upon circumstances alleged to be inconsistent with such representations and/or warranties contained in this Agreement. Further, the Company shall indemnify and
hold harmless Danforth and any of its subcontractors against any claims, losses, damages or liabilities (or actions in respect thereof) that arise out of or are based on the Services performed hereunder, except for any such claims, losses, damages
or liabilities arising out of the gross negligence or willful misconduct of Danforth or any of its employees or subcontractors. The Company will endeavor to add Danforth and any applicable employee or subcontractor to its insurance policies as
additional insureds, including without limitation the Company’s Directors and Officers liability insurance. 
 13. Independent
Contractor. Danforth and its employees and subcontractors are not, nor shall any of them be deemed to be at any time during the term of this Agreement, an employee of the Company, and therefore neither Danforth nor its employees or
subcontractors shall be entitled to any benefits provided by the Company to its employees. Danforth’s status and relationship with the Company shall be that of an independent contractor and consultant. Danforth shall not state or imply,
directly or indirectly, that Danforth is empowered to bind the Company without the Company’s prior written consent. Nothing herein shall create, expressly or by implication, a partnership, joint venture or other association between the parties.
Danforth will be solely responsible for payment of all federal, state and local taxes and contributions imposed or required on income, and for all unemployment insurance, social security contributions and all other charges and taxes arising from
this Agreement and the use of any of Danforth’s employees or subcontractors to perform services under this Agreement. 
 14.
Records. Upon termination of Danforth’s relationship with the Company, Danforth shall deliver to the Company any property or Confidential Information of the Company relating to the Services which may be in its possession including
products, project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or photocopies and any such information stored using electronic medium. 

  
 4 

 15. Notices. Any notice under this Agreement shall be in writing (except in the case of
verbal communications, emails and teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery, one day after being sent via a reputable nationwide overnight courier service or two
days after deposit in the mail or on the next business day following transmittal via facsimile. Notices under this Agreement shall be sent to the following representatives of the Parties: 

If to the Company: 
  

	 	Name:	Stephen Yoder 

	 	Title:	Chief Executive Officer 

	 	Address:	Lise-Meitner-Strasse 30 
85354 Freising-Weihenstephan 
Germany 

  

	 	Phone:	

	 	E-mail:	

 If to Danforth: 
  

	 	Name:	Gregg Beloff 

	 	Title:	Managing Director 

	 	Address:	

	 	Phone:	

	 	E-mail:	

 16. Assignment and Successors. This Agreement may not be assigned by a Party without
the consent of the other which consent shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of
all or substantially all of its assets or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. 

17. Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth in this Agreement, and
neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of either Party. In the event of such force majeure, the Party affected thereby shall use
reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 
 18. Headings. The Section
headings are intended for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

19. Integration; Severability. This Agreement is the sole agreement with respect to the subject matter hereof and shall supersede all
other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed unenforceable, it is the intention of
the Parties that the remainder of the Agreement shall not be affected. 

  
 5 

 20. Governing Law. This Agreement shall be governed by and construed in accordance with
the laws of the Commonwealth of Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of or related in any way to this Agreement shall be brought solely in a Federal or State court of
competent jurisdiction sitting in the Commonwealth of Massachusetts. 
 21. Counterparts. This Agreement may be executed in
counterparts, each of which will be deemed an original, but all of which together will constitute one agreement. 
 If you are in agreement
with the foregoing, please sign where indicated below, whereupon this Agreement shall become effective as of the Effective Date. 
  

									
	DANFORTH ADVISORS, LLC	 		 	PIERIS PHARMACEUTICALS, INC.
					
	By:	 	/s/ Gregg Beloff	 		 	By:	 	/s/ Stephen S. Yoder
					
	Print Name:	 	Gregg Beloff	 		 	Print Name:	 	Stephen Yoder
					
	Title:	 	Managing Director	 		 	Title:	 	Chief Executive Officer
					
	Date:	 	1/24/17	 		 	Date:	 	27 January 2017

  
 6 

 EXHIBIT A 

Description of Services and Schedule of Fees 

Danforth will perform mutually agreed to finance and accounting functions (the “Services”) which are necessary to support the management and
operations of the Company, certain of which are set forth below. 
 CFO Services: 

 

	 	•	 	Ensure compliance with SEC filing and other regulatory requirements, and manage related systems 

  

	 	–	 	Preparation and/or review of periodic SEC filings 

  

	 	–	 	Certification of SEC filings, as the principal financial officer and principal accounting officer commencing with the Form 10-K for the year ended December 31, 2016 

 

	 	•	 	Leadership of investor relations activities 

  

	 	–	 	Participation in quarterly earnings calls 

  

	 	–	 	Participation in drafting investor communications (press releases, annual report, etc.) 

  

	 	–	 	Meetings/calls with investor community and analysts, as appropriate 

  

	 	–	 	Develop and execute strategy for improving liquidity of Pieris’ stock 

  

	 	•	 	Oversee the finance and accounting functions 

  

	 	–	 	Management of accounting and finance team 

  

	 	–	 	Establish priorities 

  

	 	–	 	Review of internal control procedures, systems and resources to ensure propriety and adequacy 

  

	 	•	 	Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance 

  

	 	•	 	Management of treasury function 

  

	 	–	 	Currency matters 

  

	 	–	 	Banking relationships 

  
 7 

	 	–	 	Investment policy 

  

	 	–	 	Risk management and insurance 

  

	 	•	 	Participate in longer-term strategic planning process 

  

	 	•	 	Provide financial support for strategic business planning and business development/licensing opportunities 

  

	 	•	 	Participate in financing activities, including additional capital raises and/or debt and equity restructurings 

  

	 	•	 	Perform financial modeling, planning and analysis 

  

	 	•	 	Strategic opportunity assessment 

  

	 	•	 	Stock option plan management 

 The Services provided above will be provided by Lance Thibault who shall be
appointed as Acting Chief Financial Officer of the Company. Recognizing the need to prioritize activities and refine the definition and scope of the Services to be provided, Danforth shall review the list of Services with the Company’s CEO on a
periodic basis to ensure alignment and establish clear expectations. 
 Financial Terms: 

Danforth will provide the Services outlined for an hourly fee, as follows: 

CFO: Lance Thibault $300/hour 
 The Services shall be
provided for a minimum of six months, beginning on the Effective Date. 
 Travel time will be charged at $150 per hour, and in no event will
travel time be charged for more than six hours per day. In additional, the Company will reimburse Danforth for reasonable out-of-pocket business expenses to the extent set forth in Section 2 of the Agreement. 

Equity Compensation: To Be Discussed 
 The Company shall
in the sole discretion of its Board of Directors consider whether or not to grant equity to Danforth in an amount commensurate with similar positions at similar companies, and reflective of the duration of the assignment. 

  
 8EX-10.30

 Exhibit 10.30 

PIERIS PHARMACEUTICALS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 

The Board of Directors of Pieris Pharmaceuticals, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as of
January 1, 2017 (“Effective Time”), to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. 

Applicable Persons 
 This Policy shall
apply to each director of the Company who is not an employee of the Company or any Affiliate (each, a “Non-Employee Director”). “Affiliate” shall mean an entity which is a
direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended. 

Stock Option Grants 
 All stock option
amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other recapitalization affecting the Company’s common stock. 

Annual Stock Option Grants 

Annually, each Non-Employee Director shall be granted a
non-qualified stock option to purchase 20,000 shares of the Company’s common stock under the Company’s 2014 Stock Incentive Plan (the “Stock Plan”) on January 25 of each year.

 Initial Stock Option Grant For Newly Appointed or Elected Directors 

Each new Non-Employee Director shall be granted a non-qualified
stock option to purchase 30,000 shares of the Company’s common stock under the Stock Plan at the first regularly scheduled meeting of the Board of Directors on or after his or her initial appointment or election to the Board of Directors. 

Terms for All Option Grants 

Unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, all options granted under this Policy
shall (i) vest in equal quarterly installments at the end of each quarter following the grant date until the end of the fiscal year in which the grant was made, subject to the Non-Employee Director’s
continued service on the Board of Directors; (ii) have an exercise price equal to the fair market value of the Company’s common stock as determined in the Stock Plan on the grant date; (iii) terminate ten years after the grant date
and (iv) contain such other terms and conditions as set forth in the form of option agreement approved by the Board of Directors or the Compensation Committee prior to the grant date. 

 Annual Fees 

Each Non-Employee Directors serving on the Board of Directors and the Audit Committee, Compensation
Committee and/or Nominating and Corporate Governance Committee, as applicable, shall be entitled to the following annual amounts (the “Annual Fees”): 
  

									
	 Board of Directors or

Committee of Board of

Directors
	  	Annual Retainer Amount
for Member	 	  	Annual Retainer Amount
for Chair	 
	 Board of Directors
	  	$	35,000	 	  	$	25,000	 
	 Audit Committee
	  	$	7,500	 	  	$	15,000	 
	 Compensation Committee
	  	$	5,000	 	  	$	10,000	 
	 Nominating and Corporate Governance Committee
	  	$	3,750	 	  	$	7,500	 

 Except as otherwise set forth in this Policy, all Annual Fees shall be paid for the period from January 1
through December 31 of each year. Such Annual Fees shall be paid in cash or a grant of an option to purchase common stock under the Stock Plan, at the election of each Non-Employee Director, as follows:

  

	 	•	 	cash in the amount of each Non-Employee Director’s Annual Fees; or 

  

	 	•	 	an option to purchase such number of shares of the Company’s common stock as is equal to the full dollar amount of each Non-Employee Director’s Annual Fees (as
calculated below under “Calculation of Shares and Grant Terms”); or 

 Election 

Each Non-Employee Director shall make an annual election on the form provided by the Company,
indicating the combination of cash and/or common stock elected in the year prior to the payment, indicating his or her election for the following fiscal year. If no election has been made prior to the first date of fiscal year, then the Non-Employee Director shall receive all Annual Fees in cash. Each newly elected or appointed Non-Employee Director shall make an election prior to the beginning of the next
calendar quarter after his or her initial appointment or election. 
 Payments 

Payments payable to Non-Employee Directors shall be paid quarterly in arrears promptly following the
end of each fiscal quarter, provided that (i) the amount of such payment shall be prorated for any portion of such quarter that such director was not serving on the Board or a committee and (ii) no fee shall be payable in respect of any
period prior to the date such director was elected to the Board or a committee. 

  
 2 

 Calculation of Shares and Grant Terms 

If an option to purchase shares of common stock are to be received as payment, the number of shares underlying such option shall equal the
Black Scholes value of the options computed in accordance with FASB Topic 718 on the 25th day of the month following the end of each fiscal quarter (the “Calculation Date”) (rounded down to the nearest whole number so that no
fractional shares shall be issued). The option shall be automatically and without any further action required by the Board of Directors issued as of the Calculation Date. 

Expenses 
 Upon presentation of
documentation of such expenses reasonably satisfactory to the Company, each Non-Employee Director shall be reimbursed for his or her reasonable
out-of-pocket business expenses incurred in connection with attending meetings of the Board of Directors and committees thereof or in connection with other business
related to the Board of Directors. 
 Amendments 

The Compensation Committee shall periodically review this Policy to assess whether any amendments in the type and amount of compensation
provided herein should be made and shall make recommendations to the Board of Directors for its approval of any amendments to this Policy. 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00269-of-00352.parquet"}]]